Evidence map›Paper›PMID 29185187›Full record

ReviewJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2018

Extracellular Vesicle Biology in Alzheimer's Disease and Related Tauopathy.

Annina M DeLeo, Tsuneya Ikezu

Abstract readReview
In one paragraph

Review in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Extracellular Vesicle-Mediated Neuron-Glia Communications in the Central Nervous System.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2024
    Review
  11. Cell-cell communication: new insights and clinical implications.Signal transduction and targeted therapy · 2024
    Review
  12. Review
  13. Review
  14. Review
  15. Extracellular vesicles as tools and targets in therapy for diseases.Signal transduction and targeted therapy · 2024
    Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Annina M DeLeoLaboratory of Molecular NeuroTherapeutics, Department of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, 72 East Concord St, L-606, Boston, MA, 02118, USA. adeleo@bu.edu.
Tsuneya IkezuLaboratory of Molecular NeuroTherapeutics, Department of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, 72 East Concord St, L-606, Boston, MA, 02118, USA. tikezu@bu.edu.ORCID 0000-0002-3979-8596

Funding

Exosome-mediated propagation of pathogenic tau proteinRF1AG054199 · NIA · MAYO CLINIC JACKSONVILLE · PI IKEZU, TSUNEYA · 2016 to 2021
$5.0M
Targeting the miR-155 and APOE-TREM2 pathways to restore dysfunctional microglia in Alzheimer’s diseaseR01AG054672 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI BUTOVSKY, OLEG, IKEZU, TSUNEYA · 2017 to 2021
$4.1M
NIA NIH HHS R01 AG054672NIA NIH HHS RF1 AG054199
6 · The paper itself

Abstract

Extracellular vesicles (EVs) are physiological vesicles secreted from most eukaryotes and contain cargos of their cell of origin. EVs, and particularly a subset of EV known as exosomes, are emerging as key mediators of cell to cell communication and waste management for cells both during normal organismal function and in disease. In this review, we investigate the rapidly growing field of exosome biology, their biogenesis, cargo loading, and uptake by other cells. We particularly consider the role of exosomes in Alzheimer's disease, both as a pathogenic agent and as a disease biomarker. We also explore the emerging role of exosomes in chronic traumatic encephalopathy. Finally, we highlight open questions in these fields and the possible use of exosomes as therapeutic targets and agents.

Indexed as

Extracellular SpaceAlzheimer DiseaseAnimalsExtracellular VesiclesHumansTauopathiesAlzheimer’s diseaseAmyloid-β peptideChronic traumatic encephalopathyExosomesExtracellular vesiclesMicrogliaMicrotubule-associated protein tauMicrovesiclesTauopathy

Identifiers

PMID29185187
PMCPMC5972041

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.